Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why? -- Ignore unavailable to you. Want to Upgrade?

To: Shege Dambanza who wrote (334)	10/21/1997 1:27:00 PM
From: t-boy	Respond to of 763

Maybe Scopus isn't the only ones using despiration pricing tactics... Actually as I think about this move there are several advantages that stand out: (1) Suggest the idea that Remedy has better performance and architecture than its competitors. (2) Pursue competitors base will provide potential sales AND undermine competitors maintenance income. However, competitive pricing tactics like these suggest despiration and if others follow suit, it will destroy the sector's profitablity. Shege, do you think this is an indication of strength or weakness? If weakness then which of the listed competitors is gaining... Bendata, DK Systems, Magic Solutions, McAfee, Molloy Group, PHD, or Royal Blue?